Companies: 10,795·Total market cap: $144.5T
Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V.

GNMLFOTCHealthcare● Active
$0.95
$-0.13(-12.04%)
Market Cap$928865018
P/E Ratio
52W High$1.17
52W Low$0.91
Overview

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

GNMLF · shares outstanding · updated Jun 10, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
974.2M -0.43% YoY Change
FY · as of Dec 31, 2025 · Reported in MXN
vs 978.4M in FY 2024
Diluted Shares Outstanding
974.2M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
-0.43%
year-over-year
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-10

Shares Outstanding Growth Rate

3-Year CAGRdeclining
-0.6%
2022 → 2025
5-Year CAGRdeclining
-0.8%
2020 → 2025
10-Year CAGRdeclining
-0.6%
2015 → 2025

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 974.2M
974.2M
-0.43%
FY 2024
Diluted Shares: 978.4M
978.4M
+2.20%
FY 2023
Diluted Shares: 957.3M
957.3M
-3.61%
FY 2022
Diluted Shares: 993.2M
993.2M
-1.43%
FY 2021
Diluted Shares: 1.008B
1.008B
-0.41%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs GNMLF
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+156.8%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+149.3%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+82.8%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+59.1%
#5
Genomma Lab Internacional, S.A.B. de C.V.GNMLF
Genomma Lab Internacional, S.A.B. de C.V.YOU
974.2M
#6
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M-6.6%
#7
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M-7.8%

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, Genomma Lab Internacional, S.A.B. de C.V. reports 974.2M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Genomma Lab Internacional, S.A.B. de C.V.'s basic shares outstanding (974.2M) represents currently issued shares. Diluted shares outstanding (974.2M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

Genomma Lab Internacional, S.A.B. de C.V.'s float is — (— of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · MXN

About shares outstanding & methodology

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) shares outstanding history from 2006 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Genomma Lab Internacional, S.A.B. de C.V. shares outstanding for the fiscal year ending December 31, 2025 were 974.2M, a 0.43% decline year-over-year. Genomma Lab Internacional, S.A.B. de C.V. FY 2025 shares outstanding were 974.2M, a -0.43% decline from FY 2024.

Genomma Lab Internacional, S.A.B. de C.V. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of -0.6% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

GNMLF shares outstanding · 4 questions

As of December 31, 2025, Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) has approximately 974.2M basic shares outstanding and 974.2M diluted shares outstanding. This represents a -0.43% year-over-year change from FY 2024 (978.4M). Genomma Lab Internacional, S.A.B. de C.V.'s declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.

GNMLF shares outstandinghow many shares does GNMLF haveGNMLF basic shares 2025GNMLF diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Genomma Lab Internacional, S.A.B. de C.V. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-10